Pharmaceutical technology transfer: from dossier to validated commercial production

1. Define what a successful transfer must prove

Start with a written transfer mandate: the product, presentations, markets, sending unit, receiving unit, intended batch scale, commercial purpose, responsibilities, regulatory pathway and target supply date. Define success in terms of capability and evidence—not completion of activities.

• The receiving unit understands the product, process and control strategy.
• Facilities, utilities, equipment, materials, methods, people and data systems are suitable.
• Differences from development, the sending unit and the approved dossier are assessed and controlled.
• Engineering, validation or registration batches meet predefined scientific acceptance criteria.
• Required regulatory approvals or notifications are effective before commercial use.
• The first commercial batches can be reviewed, released, supplied and monitored through routine systems.

2. Establish governance, decision rights and the regulatory boundary

Appoint accountable transfer leads at both units and create one cross-functional transfer team covering development or the sending site, production, packaging, engineering, QC, QA, validation, regulatory affairs, supply, procurement, IT/data and EHS. A quality agreement or technical agreement should clarify responsibilities where separate legal entities are involved.

Run the work under the pharmaceutical quality system. Use an approved transfer plan or protocol, controlled change records, a risk register, action log, meeting cadence, escalation rules and formal stage-gate decisions. Quality oversight must remain independent from schedule pressure.

3. Build and accept the product knowledge package

The sending unit should transfer organized, traceable knowledge—not a document dump. The receiving unit should inventory what was received, assess completeness, resolve contradictions and identify tacit knowledge that requires observation, demonstration or supervised practice.

4. Convert differences into a controlled receiving-site gap assessment

Compare the intended receiving process with development knowledge, the sending process and the approved registration. Record every meaningful difference, its potential effect, detectability, evidence needed, regulatory category, owner and closure decision. Similar equipment names do not prove equivalence.

• Batch size, equipment geometry, working volume and scale-up relationships
• Mixing, granulation, drying, compression, filling or coating energy and control modes
• HVAC classification, temperature, humidity, water, gases and power resilience
• Material sources, grades, particle attributes and local testing capability
• Sampling locations, instruments, software, calculations and data review
• Packaging line capability, local components, artwork, coding and market presentation
• Cleaning method, shared-facility hazards and campaign strategy
• Dossier commitments, pharmacopoeial editions, national requirements and variation timing

5. Establish material, supplier, facility and equipment readiness

Secure approved sources and representative lots early enough for characterization, method work, engineering batches, validation and stability. Where the receiving unit proposes a different supplier, grade, packaging component or test site, route it through technical, quality and regulatory assessment before use.

Translate process requirements into approved user requirements and qualification evidence. Confirm capacity, operating ranges, instrumentation, calibration, maintenance, software, data integrity, containment, cleaning access, utilities and failure recovery. Resolve critical punch items before product exposure.

• Material and component specifications are aligned with the dossier and process needs.
• Supplier qualification and quality agreements cover change notification and traceability.
• Rooms, flows and utilities support the product and contamination-control strategy.
• Equipment qualification covers intended operating ranges and product-specific functions.
• Critical spares, service support and backup arrangements are realistic for the receiving country.
• Warehouse, sampling, dispensing and status controls are ready before transfer lots arrive.

6. Transfer manufacturing and packaging as an understood process

Create receiving-site master documents from approved knowledge and site capability. Do not copy sending-site parameters blindly. Link each critical or key parameter to its purpose, acceptable range, monitoring method, response to drift and relevant quality attribute.

• Conduct structured floor-level walkthroughs and operator-to-operator knowledge transfer.
• Define set-points, proven ranges, IPCs, sampling, yields, reconciliation and hold times.
• Predefine how scale, equipment and environmental differences will be evaluated.
• Use engineering batches to learn—not to disguise unapproved commercial production.
• Record interventions, adjustments, alarms, stoppages and observations contemporaneously.
• Transfer packaging component control, line clearance, vision systems, coding and reconciliation.
• Investigate unexpected results before changing the protocol, process or acceptance criteria.

7. Demonstrate analytical-procedure transfer and laboratory capability

The receiving laboratory must understand the method and demonstrate suitable performance with its analysts, instruments, reagents, standards, columns, software and environment. Choose comparative testing, co-validation, method verification, complete or partial revalidation, or a justified waiver based on method status, complexity, laboratory experience and risk.

8. Connect qualification, cleaning, process validation and stability

A transfer does not sit outside the validation lifecycle. Close facility, utility, equipment, computerized-system, method and cleaning prerequisites before process performance qualification. The PPQ strategy should reflect transferred knowledge, site differences, residual risk, scale, variability and the intended commercial process.

• Approve the validation master strategy and product-specific protocol before execution.
• Justify batch number, material lots, operating conditions, sampling and acceptance criteria scientifically.
• Evaluate within-batch and between-batch variability—not only specification compliance.
• Assess cleaning validation, campaign length, dirty/clean hold times and shared-facility risk.
• Place representative batches on the required stability programme and track commitments.
• Define enhanced monitoring and continued process verification before commercial release.

9. Execute through controlled gates and preserve the complete record

Each gate should state the evidence reviewed, open actions, residual risk, decision authority and conditions for progression. Deviations and changes must remain visible; they should not disappear into meeting minutes or revised documents. The final transfer report should reconcile the protocol, results, departures, investigations, commitments and conclusion.

10. Worked Africa–India transfer example

An established immediate-release tablet is transferred from an Indian sending unit to an African receiving unit. The formula is unchanged, but the receiving site has a different granulator and dryer, lower-capacity HVAC, a different blister machine, longer imported-material lead times and a national registration that names the original manufacturing site and suppliers.

• Regulatory first: map the site addition, manufacturing change, supplier status, comparative data, validation batches and approval timing for every intended market.
• Process fit: compare equipment geometry, minimum/maximum loads, binder delivery, granulation endpoint, drying airflow and compression dwell time.
• Materials: secure representative API, excipient and packaging lots; do not assume future import lots will behave like development samples.
• Laboratory: transfer assay, dissolution, impurities and cleaning methods with controlled standards, columns, software and raw-data review.
• Resilience: qualify backup power and environmental recovery, plan critical spares and allow customs/forex lead time in the validation schedule.
• Launch: obtain required approvals, complete PPQ and stability commitments, review the first commercial batches under enhanced monitoring and formally hand over to routine operations.

11. Common technology-transfer failures

• Starting from a target launch date without a defined regulatory critical path
• Treating the dossier and master formula as the complete knowledge package
• Copying sending-site settings without assessing equipment and scale differences
• Discovering method, standard or column shortages during validation
• Using engineering batches before materials, methods or documents are controlled
• Changing acceptance criteria after results are available
• Running PPQ with unresolved qualification, cleaning or data-system gaps
• Failing to include packaging, stability, distribution and artwork in the transfer scope
• Closing the project at the last PPQ batch instead of after controlled commercial handover
• Losing tacit knowledge because training records show attendance but not demonstrated competence